Endocrine Abstracts

Objective: Immune checkpoint inhibitors (ICI) are used for treatment of non-small cell lung cancer (NSCLC) and are associated with immune-related adverse events (irAEs), especially thyroid dysfunction. Few studies found an association between thyroid dysfunction and response to Nivolumab in the NSCLC The objective of this retrospective cohort study was to investigate the association between the occurrence of thyroid dysfunction in patients treated with Nivolumab for a NSCLC an...